ONWARD Medical B.V.

Onward Medical reports that two additional patients have been treated in the ARC-BCI study, bringing the total to seven participants who have received the combined brain–computer interface and implantable spinal cord stimulation. The company emphasizes ongoing insights from the feasibility study and plans further scientific publications. With a market capitalization of around €250 million, the report sees significant upside potential for Onward Medical in the growing neurotech sector. » More on deraktionaer.de

OpenAI wrote the largest check in a $250 million funding round for Merge Labs (valuation $850 million), which researches brain-computer interfaces (BCI). Renewed interest in neurotech could boost publicly traded Onward Medical, which is working on an ARC-BCI system and already has a therapy system on the market. Onward has a market capitalization of about €250 million; earlier test results are seen as promising, so investors see share-price upside if interest in neurotech increases. » More on deraktionaer.de

The FDA has expanded approval for ONWARD Medical’s non-invasive ARC-EX system to include at-home use; the device delivers transcutaneous spinal cord stimulation to improve hand strength and sensation in adults with incomplete spinal cord injuries. ONWARD reports growing sales and, for the first time, quarterly revenue above €1m after selling 40 units in Q3; the system also carries CE marking for the EU. The company is expanding its commercial presence but is burning cash quickly, although it holds more liquid assets than debt. » More on de.investing.com